Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.


Innovative gene editing tool

Poseida, Demeetra and Hera BioLabs have recently launched a new tool for the targeted alteration of genes that offers an attractive alternative to the widely used CRISPR-Cas9 method. Their system, Cas-CLOVER™, employs the endonuclease Clo51, discovered and characterized by Dr Ralf Kühn* at the Institute of Developmental Genetics of the Helmholtz Zentrum München. The Helmholtz Zentrum München has patented this technology in collaboration with Ascenion to create a solid basis for its commercialization.
The three companies have acquired exclusive licences for Clo51 and, by fusing the enzyme to inactive Cas9, have created a system that is just as efficient as CRISPR-Cas9, but more precise, as no off-target activity has been observed. This confers a significant advantage, particularly for the development of gene therapies.

The method will be made broadly available by the companies: Poseida develops innovative approaches to cellular immunotherapy and gene therapy, Demeetra supports applications in industrial biotechnology and agriculture, and Hera BioLabs provides services in drug discovery and pre-clinical research. In addition, third parties may acquire licences to use the Cas-CLOVER™ technology as a research tool.

*at the Max Delbrück Center for Molecular Medicine (MDC) since 2014.